Fresh Competition Coming For Narcan In US
Amphastar Receives Approval For 505(b)(2) Naloxone As Amneal Files Generic
Executive Summary
Further US hybrid and generic rivals to Narcan are in the works, with Amphastar having just received an FDA nod for its naloxone nasal spray in a proprietary device as Amneal files an ANDA for a further generic version.
You may also be interested in...
Amneal Continues To See Value In Complexity
With Amneal delivering what it described as a “solid” set of financials for 2022, the company has reaffirmed that it sees more value in moving increasingly into complex generics and bolstering its nascent biosimilars business.
After US FDA Advisors Unanimously Back First OTC Naloxone Proposal, Meeting On Second Not Needed
“Meeting is no longer needed,” agency states in announcement. The same committees’ unanimous recommendation during a meeting in February on Emergent’s sNDA for OTC sales of 4-mg naloxone nasal spray made a repeat for HRT’s NDA for 3-mg spray unnecessary.
Urgency For Approval Of OTC Naloxone In US Weighed Against Using Untested Package Labeling
All members of joint advisory panel noted urgent need to expand access to naloxone and voted yes on OTC sales of Emergent's Narcan nasal spray, but many also pointed out concerns for testing needed for DFl Facts label firm unveiled to the panel as well as to FDA officials during meeting.